Table 1.
Studies Comparing SCIG With IVIG Therapy: Study and Patient Characteristics
| Author, Year | Country | Centres(N) | Design | Patients Evaluated for Efficacy (n) | Completers (n) | Age, Years Mean ± SD (Range) | Observation Period for Efficacy (Month) | Reported Outcomes |
|---|---|---|---|---|---|---|---|---|
| Bienvenuet al, 201622 | France | 35 | Prospective/Retrospective | 116 adults with PID (46 on hospital IVIG, 57 on home SCIG, and 13 patients on home IVIG). 15 patients switched method (10 from IVIG to SCIG, 2 from SCIG to IVIG, 2 from hospital IVIG to home IVIG, and 1 from home IVIG to SCIG). |
All | 41.8 ± 17.5 (15–84) | SCIG: 12 IVIG: 12 |
Infection, SF-36, LQI |
| Vultaggioet al, 201523 | Italy | 11 | Prospective/Retrospective | 43 adults and 7 children with PID. 44 patients switched from IVIG to SCIG and 6 patients changed their SCIG preparation. Retrospective data were analyzed for 41 patients. |
39 (per protocol). 44 (ITT). | 31.7 ± 15.7 | SCIG: 24 IVIG: 12 |
Infection, trough level, hospitalization, missed school/work days, SF-36, CHQ-PF50, LQI, adverse events |
| Compagno et al, 201420 | Italy | 1 | Retrospective | 61 adults with SID. 33 patients had been previously treated with IVIG. |
43 | 67.7 | Mean SCIG: 19 IVIG: 42 |
Infection, trough level, antibiotic use, adverse events |
| Samaan et al, 201424 | Quebec, Canada | 1 | Retrospective | 143 children who had been given the choice of IVIG or SCIG. | N/A | Switch cohort: 10.7 New cohort: 6.0 |
NA | Preference |
| Reid and Pires, 201425 | Ontario, Canada | 1 | Survey | 91 adults & children on IVIG were sent a survey. | N/A | 23 ± 15 (2–75) | NA | Preference |
| Bezrodnik et al, 201326 | Argentina | 3 | Prospective/Retrospective | 15 children with PID previously on IVIG were switched to SCIG. | 13 | 10.6 ± 3.7 | SCIG: 8.5 IVIG: 8.5 |
Infection, trough level, hospitalization, adverse events |
| Sundin et al, 201221 | Sweden | 1 | Retrospective & survey | 58 children with SID due to stem cell transplantation were treated with IG (12 with SCIG and 46 with IVIG). | N/A | SCIG: 2.6 (0–9) IVIG: 7.2 (0–17) |
Median SCIG: 9 IVIG: 5 |
Infection, family attitudes, adverse events |
| Hoffmannet al, 201017 | Germany | 24 | Prospective | 19 adults & 11 children (25 PID & 5 SID) previously on IVIG were shifted to SCIG. | All | 30 (3–74) | SCIG: 9 IVIG: N/A |
Trough level, SF-36, CHQ-PF50, preference, adverse events |
| Bergeret al, 20108 | USA | Multia | Prospective | 42 adults and 9 children with PID previously on IVIG were treated with SCIG. | 45 | 40.4 ± 20.24 (3–66) | SCIG: 12 IVIG: NA |
Infection, trough level, missed school/work days, SF-36, CHQ-PF50, adverse events |
| Thepotet al, 201015 | France | 1 | Prospective | 65 adults with PID receiving IVIG were switched to SCIG. | 60 | 43.8 (15–73) | SCIG: 12 IVIG: 12 |
Trough level, hospitalization, adverse events |
| Quintiet al, 200827 | Germany | Multia | Prospective | 12 adults & 1 child, all with PID who were not receiving immunoglobulin for long period because of severe adverse reactions resumed their therapy using SCIG. | All | 41.2 (13–67) | SCIG: 12 IVIG: NA |
Trough level, adverse events |
| Fasth & Nystrom, 200814 & Fasth & Nystrom, 200728 | Sweden | 1 | Prospective | 12 children with PID were switched from IVIG to SCIG and were followed for 6 months. | All | 10.9 (1.7–17.1) | SCIG: 6 IVIG: 6 |
Trough level, antibiotic use, hospitalization, missed school/work days, CHQ-P50 and CHQ child form, preference, adverse events |
| Nicolay et al, 200629 | USA & Canada | Multia | Prospective | 28 adults with PID were switched to SCIG. | 21 | 36.1 ± 13.6 | 12 | SF-36, LQI, preference |
| Kittner et al, 200630 | Germany | Multia | Survey | 61 adults with PID filled a questionnaire deigned to gather opinions on switching to SCIG. | SCIG: 37± 9.1 IVIG: 51.2 ± 14.5 |
NA | Preference | |
| Gardulf et al, 2004,9 Nicolay et al, 2005,31 & Gardulf et al 20067 | 6 European countries |
12 | Prospective | 44 adults and 16 children with PID were switched from IVIG to SCIG. 10 patients were previously on SCIG. | 52 | Median Adults 33.5 (14–74) Children 7 (3–13) |
SCIG: 10 IVIG: ≥ 6 |
Infection, trough level, hospitalization, missed school/work days, SF-36, CHQ-PF50, LQI, preference, adverse events |
| Gaspar et al, 199832 | UK | 1 | Prospective/Retrospective | 26 children with PID were treated with SCIG. 15 had previously been treated with IVIG. | (1.5 months–15 years) | SCIG: 12 IVIG: 6–42 |
Parental satisfaction |
Abbreviations: CHQ-PF50, child health questionnaire-parental form 50; ID, immunodeficiency; IVIG, hospital-based intravenous immunoglobulin; LQI, life quality index; NA, not available/not applicable; PID, primary immunodeficiency; SCIG, home-based subcutaneous immunoglobulin; SID, secondary immunodeficiency; SF-36, short-form 36.
a
Precise number of centres not reported in study.